Recurrent Skin Squamous Cell Carcinoma
4 clinical trials · Condition
◉ Watch Recurrent Skin Squamous Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer (NCT04315701) | University of Southern California | 2020-06-17 |
| Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer (NCT04428671) | Emory University | 2020-05-15 |
| Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin (NCT04163952) | Rutgers, The State University of New Jersey | 2020-01-31 |
| Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma (NCT01198028) | M.D. Anderson Cancer Center | 2011-03-10 |
Track Recurrent Skin Squamous Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.